Drug intelligence / Profile preview

Senl_B19 autologous T-cell injection

Development stage: Unknown
Lead developer: Senlang Bio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Senl_B19 is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Hebei Senlang Biotechnology. The therapy involves genetically engineering a patient's own T cells to express a CAR that specifically targets the CD19 antigen, a protein widely expressed on the surface of B-cell malignancies. Once re-infused into the patient, these engineered cells recognize and eliminate CD19-positive leukemia cells. Senl_B19 is currently being evaluated in the SENCALL Phase II clinical trial in China, focusing on pediatric and young adult patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).

Other names: Senl_B19 autologous CAR-T cells

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on Senl_B19 autologous T-cell injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senl_B19 autologous T-cell injection.

Explore the full profile